Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.72 |
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350184 | 1.00 | DRD4 (0.72) | DRD4DRD2HTR1ADRD3HTR7 | |
| SCHEMBL6353491 | 0.84 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6359534 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR1AHTR7HTR2A | |
| SCHEMBL6353493 | 0.84 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6354027 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR1AHTR7HTR2A | |
| SCHEMBL6354025 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR1AHTR7HTR2A | |
| SCHEMBL6357616 | 0.82 | HTR1A (0.70) | DRD4DRD2HTR1AKDM4EALDH1A1 | |
| SCHEMBL6359138 | 0.80 | DRD4 (0.71) | DRD4DRD2HTR1AHTR7HTR2A | |
| SCHEMBL6359142 | 0.80 | DRD4 (0.71) | DRD4DRD2HTR1AHTR7HTR2A | |
| SCHEMBL6351475 | 0.79 | DRD4 (0.76) | DRD4DRD2HTR1ADRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885HTR1A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.